Algernon Health Announces Private Placement
VANCOUVER, British Columbia – Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a dynamic Canadian healthcare company, is excited to share details of its recent non-brokered private placement, which is anticipated to generate gross proceeds of $500,000. This initiative involves issuing units priced at $0.07 each.
Each unit will comprise one Class A common share and one-half of a common share purchase warrant. Holders of a full warrant can acquire one additional common share at an exercise price of $0.15 for twelve months from the issuance. After one year, this price will adjust to $0.25, and after two years, it will further increase to $0.50, reflecting the Company’s growth potential.
Details of the Offering
The offering is projected to close in several tranches, with plans to finalize by the end of November 2025. Algernon might also provide cash finder’s fees and warrants to eligible finders, reaching up to eight percent of the funds raised through investors they introduce.
The proceeds will significantly contribute towards advancing the Company’s Alzheimer’s Disease program, focusing on the establishment of its first U.S. clinic specializing in brain-specific neuroimaging. This is part of a larger strategy to enhance research and treatment for Alzheimer’s and other debilitating neurological conditions.
Use of Proceeds
Funds from this offering will directly assist in covering general operational costs, administrative expenditures, and necessary working capital. As the Company strives to expand its pioneering neuroimaging services, these resources will be invaluable.
All securities issued through this offering will be subjected to a statutory hold period of four months plus one day from issuance, adhering strictly to Canadian securities legislation.
Recent Company Developments
In addition, Algernon Health has also reported the conversion of approximately 1,268,334 subscription receipts into the same number of Series 1 preferred shares and related warrants from a previous placement completed earlier this year. This conversion is indicative of the Company’s strategic movements towards bolstering its financial standing and operational capabilities.
The adjustments to the Company’s authorized share structure also received shareholder approval, allowing for an unlimited number of preferred shares to be established, which will play a pivotal role in funding future initiatives.
The Vision Ahead
Algernon Health is dedicated to providing innovative healthcare solutions and has plans to launch a network of new clinics across North America aimed at early-stage Alzheimer’s detection. The Company also operates a subsidiary, Algernon NeuroScience, that is currently researching a unique form of DMT aimed at aiding recovery from strokes and traumatic brain injuries.
This commitment to advancing medical science and public health solidifies Algernon’s position as a significant player in the healthcare sector, further enhanced by its ownership stake in Seyltx, a U.S. drug development company focused on treating chronic coughs.
Contact Information
For further inquiries, please contact Christopher J. Moreau, CEO of Algernon Health Inc., at 604.398.4175 ext 701 or email at cjmoreau@algernonhealth.com.
About Algernon Health
Algernon Health specializes in providing brain-specific PET scanning services, facilitating the early detection of Alzheimer’s and various neurological conditions. Through their innovative approaches, they aim to enhance understanding and treatment of critical health issues that affect countless individuals.
Frequently Asked Questions
What is the purpose of Algernon Health's private placement?
The private placement aims to raise funds to support the advancement of the Company's Alzheimer’s Disease program and the establishment of a specialized neuroimaging clinic.
What companies are associated with Algernon Health?
Algernon Health operates Algernon NeuroScience, which focuses on psychedelic research for neurological recovery, and has a stake in Seyltx, which is working on chronic cough medication.
How much is Algernon Health looking to raise in its current offering?
The Company is targeting a total of $500,000 through the private placement.
What types of shares are included in the offering?
Each unit in the offering consists of one Class A common share and one-half common share purchase warrant.
What is the exercise price for the Common Warrants?
The initial exercise price is $0.15, with subsequent increases to $0.25 after 12 months and $0.50 after 24 months based on specified conditions.
